Prior Authorization Criteria — Agamree (vamorolone) for Duchenne Muscular Dystrophy
Customize your policy alerts
Sign up for all West Virginia Bureau for Medical Services (Department of Human Services) policy alerts
Know when West Virginia Bureau for Medical Services (Department of Human Services) releases new policies or updates existing guidance.
Monitor payer policy activity
This document establishes prior authorization requirements for Agamree (vamorolone) for treatment of Duchenne muscular dystrophy (DMD) in patients aged two years and older for members of the West Virginia Bureau for Medical Services.
No material clinical or coverage changes in this revision.
Coverage Criteria for Agamree (vamorolone)
Initial Therapy
Covered when ALL of the following are met:
Prior authorization shall only be granted for patients experiencing prednisone side effects where Agamree shows an improved profile; include detailed adverse effect description and baseline test results.
Continuation Therapy / Reauthorization
Reauthorization covered when ALL of the following are met:
Most recent results must be ≤ 6 months prior to the reauthorization request; acceptable measures are the same as for baseline assessments.
Prior authorization for Agamree (vamorolone) will be granted only when the request documents that the member experienced significant adverse effects from prior prednisone therapy and that switching to Agamree provides an improved side-effect profile for those specific effects. The policy requires a detailed description of the prednisone-related adverse effects and their functional impact (for example, significant psychiatric or behavioral changes affecting school or daycare, or Cushingoid effects/significant weight gain). Requests lacking documentation of at least six months continuous prednisone therapy or lacking a detailed record of significant prednisone-related adverse effects demonstrating potential improvement with Agamree do not meet the criteria and may be denied.
Coding and Key Clinical Thresholds
Provider Documentation, Authorization, and Denial Risks
Prior authorization required; approval durations
Prior authorization is required for Agamree and will be granted only if all coverage criteria are met. Initial approvals are for six months; continuation (reauthorization) approvals are for 12 months.
Required prior prednisone therapy (≥6 months) and intolerance contingency
Documented history of at least six months of continuous prednisone therapy must be submitted prior to Agamree initiation. If prednisone intolerance or significant adverse effects are present, provide detailed descriptions; prior authorization is contingent on demonstrating that Agamree offers an improved profile for those adverse effects.
- Minimum prior prednisone duration: ≥ 6 months (continuous therapy).
- If prednisone caused significant adverse effects, include a detailed description correlating to the policy definition (psychiatric/behavioral changes or Cushingoid/weight effects).
Required documentation for initial and reauthorization requests
Include the following with initial and reauthorization requests: diagnosis of Duchenne muscular dystrophy, patient age (≥2 years), prescribing clinician specialty or documentation of consultation with a neurologist or DMD/neuromuscular specialist, history of ≥6 months continuous prednisone therapy, detailed description of any prednisone-related significant adverse effects, and baseline clinical assessment using at least one acceptable test. For reauthorization, submit most recent results (≤6 months) compared to pre-treatment baseline.
- Diagnosis of Duchenne muscular dystrophy (DMD).
- Patient age (≥2 years).
- Prescribed by or in consultation with a neurologist or DMD/neuromuscular specialist.
- History of ≥6 months continuous prednisone therapy.
- Detailed description of significant prednisone-associated adverse effects.
- Baseline clinical assessment by at least one: muscle strength test (e.g., MRC), motor/walk test (e.g., 6MWT), pulmonary function test (e.g., FVC), or timed functional test.
- For reauthorization: most recent results ≤6 months prior to request showing improvement, stabilization, or resolution compared to pre-treatment baseline (or documentation that prednisone-associated adverse events were resolved with Agamree).
Denial risk if required prior therapy or adverse-effect documentation missing
Requests lacking documentation of at least six months of continuous prednisone therapy, or lacking a detailed description of significant prednisone-related adverse effects (or evidence that Agamree improves those effects), do not meet the criteria and may be denied.
- Absence of ≥6 months continuous prednisone history is a denial risk.
- Absence of detailed documentation of significant prednisone adverse effects (per policy definitions) is a denial risk.
- No demonstration that Agamree offers an improved profile for the documented prednisone side effect may result in denial.
Background on Agamree (vamorolone)
Agamree (vamorolone) is a corticosteroid indicated for treatment of Duchenne muscular dystrophy (DMD) in patients aged two years and older. This policy requires that treatment be prescribed by or in consultation with a neurologist or DMD/neuromuscular specialist and that patients have a documented history of at least six months continuous prednisone therapy prior to authorization for Agamree. Baseline clinical assessments must accompany the request using at least one accepted measure (muscle strength, motor/walk tests, pulmonary function tests, or timed functional tests) and documentation of significant prednisone-associated adverse effects as defined by the policy.
Defined Terms and Clinical Measures
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.